“This complex is primarily viewed as a laboratory for investigators working for the Center for Biologics Evaluation and Research, which regulates the blood supply, vaccines, cellular and gene therapies and human tissues,” Margaret A. Hamburg, the commissioner of Food and Drugs for the FDA, said in her remarks at the opening ceremonies. "But a portion of this complex will support the work of the Office of Biotechnology Products in our Center for Drug Evaluation and Research."
The complex consists of two office buildings and a state-of-the-art laboratory. Three biosafety suites will ensure safe handling and storage of biological specimens.
"This new lab will better support the FDA’s Medical Counter-Measure initiative, including pandemic influenza preparedness, as well as facilitating development of products to prevent global diseases such as HIV, tuberculosis and malaria, and of course Ebola," Hamburg said.
The Center for Tobacco Products and regulatory research efforts are also housed at the complex.